Antinociceptive effect of botulinum toxin type A on experimental abdominal pain

Drinovac, V.; Bach-Rojecky, Lidija; Babić, Ana; Lacković, Zdravko

doi:10.1016/j.ejphar.2014.10.038

Cited by 12 publications

(6 citation statements)

References 45 publications

(56 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although central modulation of the nociceptive activity of BoNT is largely unknown, several research results indicate that neurotransmitter receptors have linked GABA and opioid transmission to the central antinociceptive action of the toxin. Both GABA and opioid transmission have a role in the attenuation of sensory input transmitted to the dorsal horn [41][42][43]. The functional block of GABA inhibition by BoNT/A and BoNT/B in spinal cord suggests the central modulation of nociceptive activity.…”

Section: How Cns Responds To Pain Signals?mentioning

confidence: 99%

Therapeutic use of botulinum toxin in pain treatment

Kumar

2018

Neuronal Signaling

View full text Add to dashboard Cite

Correspondence: Raj Kumar (rkumar@inads.org)Botulinum toxin is one of the most potent molecule known to mankind. A neurotoxin, with high affinity for cholinergic synapse, is effectively capable of inhibiting the release of acetylcholine. On the other hand, botulinum toxin is therapeutically used for several musculoskeletal disorders. Although most of the therapeutic effect of botulinum toxin is due to temporary skeletal muscle relaxation (mainly due to inhibition of the acetylcholine release), other effects on the nervous system are also investigated. One of the therapeutically investigated areas of the botulinum neurotoxin (BoNT) is the treatment of pain. At present, it is used for several chronic pain diseases, such as myofascial syndrome, headaches, arthritis, and neuropathic pain. Although the effect of botulinum toxin in pain is mainly due to its effect on cholinergic transmission in the somatic and autonomic nervous systems, research suggests that botulinum toxin can also provide benefits related to effects on cholinergic control of cholinergic nociceptive and antinociceptive systems. Furthermore, evidence suggests that botulinum toxin can also affect central nervous system (CNS). In summary, botulinum toxin holds great potential for pain treatments. It may be also useful for the pain treatments where other methods are ineffective with no side effect(s). Further studies will establish the exact analgesic mechanisms, efficacy, and complication of botulinum toxin in chronic pain disorders, and to some extent acute pain disorders.

show abstract

Section: How Cns Responds To Pain Signals?mentioning

confidence: 99%

Therapeutic use of botulinum toxin in pain treatment

Kumar

2018

Neuronal Signaling

View full text Add to dashboard Cite

show abstract

“…In addition, the modulation of central nervous system sensory receptors in peripheral organs after BoNT-A injection has been observed in animal studies. The reduction of c-fos and calcitonin gene-related peptide expression levels in the dorsal horn of the spinal cord after pawl BoNT-A injection has been reported in association with the reduction of mechanical allodynia [33,34]. In a recent study, the injection of radiolabeled BoNT-A into the bladder caused retrograde transport to lumbosacral dorsal root ganglia [35].…”

Section: Resultsmentioning

confidence: 99%

Using Botulinum Toxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome—Possible Pathomechanisms and Practical Issues

Jhang

2019

Toxins

View full text Add to dashboard Cite

Treatment for patients with interstitial cystitis/bladder pain syndrome (IC/BPS) is always challenging for urologists. The main mechanism of the botulinum toxin A (BoNT-A) is inhibition of muscle contraction, but the indirect sensory modulation and anti-inflammatory effect in the bladder also play important roles in treating patients with IC/BPS. Although current guidelines consider BoNT-A injection to be a standard treatment, some practical issues remain debatable. Most clinical evidence of this treatment comes from retrospective uncontrolled studies, and only two randomized placebo-control studies with limited patient numbers have been published. Although 100 U BoNT-A is effective for most patients with IC/BPS, the potential efficacy of 200 U BoNT-A has not been evaluated. Both trigone and diffuse body BoNT-A injections are effective and safe for IC/BPS, although comparison studies are lacking. For IC/BPS patients with Hunner’s lesion, the efficacy of BoNT-A injection remains controversial. Most patients with IC/BPS experience symptomatic relapse at six to nine months after a BoNT-A injection, although repeated injections exhibit a persistent therapeutic effect in long-term follow-up. Further randomized placebo-controlled studies with a larger number of patients are needed to support BoNT-A as standard treatment for patients with IC/BPS.

show abstract

“…It is likely that such sensitizations from damage or inflammation of knee joint increased pain, which was difficult to control with conventional therapy (26,27). Lately, it was found that BoNT-A was able to block peripheral and central sensitizations by inhibiting releasing neurotransmitters from primary sensory neurones in a rat formalin model, which was produced by injecting formalin into rat paw (28) and reducing c-Fos expression in the dorsal horn of the spinal cord (28,29). Increased c-Fos expression may indicate increased neuronal activation through harmful stimuli.…”

Section: Mechanism Of Effect Of Bont-a and Hyaluronatementioning

confidence: 99%